Please provide your email address to receive an email when new articles are posted on . More than 90% of patients with hyperphosphatemia reached serum phosphate less than 5.5 mg/dL. Pills were seven ...

Please provide your email address to receive an email when new articles are posted on . Of survey respondents, 47% said large number and large size of pills were among top phosphate binder adherence ...

LOS ALTOS, Calif., Nov. 29, 2021 /PRNewswire/ -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today ...

LOS ALTOS, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics (UNCY), Inc. , a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or ...

LOS ALTOS, Calif., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the ...

HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI - News) today announced that it has submitted an investigational new drug (IND) application to the U.S. Food & Drug ...

– Patients preferred OLC more than 4 to 1 over their prior phosphate binder therapy – – Median daily pill burden reduced by half after switch to OLC – LOS ALTOS, Calif., July 10, 2024 (GLOBE NEWSWIRE) ...

Basingstoke, UK – 30 June 2003 - Treatment with Fosrenol® (lanthanum carbonate) initiates rapid, statistically significant reductions in serum phosphate within one week of starting therapy (p 0.0001), ...

The problem of phosphate accumulation became apparent quite early in the history of dialysis. Soft tissue and vascular calcification could often be clearly visualised on plain x-ray because of calcium ...

Systematic reviews on this topic have largely been focused on patients receiving dialysis. The benefits of phosphate-lowering medications on clinical outcomes in patients with nondialysis-dependent ...